Seres Therapeutics (MCRB) Change in Accured Expenses (2014 - 2026)

Seres Therapeutics has reported Change in Accured Expenses for 13 years, with the latest figure at -$1.0 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 76.47% year-over-year to -$1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.1 million (up 70.07% YoY) and the FY2025 annual result came in at -$6.5 million, up 36.17% from the prior year.
• Change in Accured Expenses climbed to -$1.0 million in Q1 2026 per MCRB's latest filing, from -$2.3 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $26.6 million in Q4 2023 and troughed at -$19.0 million in Q1 2023.
• A 5-year average of $83823.5 and a median of -$1.0 million in 2026 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses surged 6495.04% in 2023, then slumped 756.87% in 2024.
• Over 5 years, Change in Accured Expenses stood at $403000.0 in 2022, then soared by 6495.04% to $26.6 million in 2023, then slumped by 126.12% to -$6.9 million in 2024, then soared by 66.19% to -$2.3 million in 2025, then jumped by 55.48% to -$1.0 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$1.0 million, -$2.3 million, and $633000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.